TrialThe oncologist2026

Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): a phase II study (NIRA-PANC).

Anup Kasi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.